多发性硬化登记型药物警戒的机遇与挑战:REGIMS登记实施经验
本文以德国多发性硬化免疫治疗登记REGIMS为例,阐述登记型药物警戒的机遇与挑战。REGIMS为观察性多中心临床登记,旨在评估多发性硬化免疫治疗副作用的发生率、类型和后果。截至2019年底43个中心活跃招募,前1000例患者中女性69.3%、复发缓解型89.8%,多接受二线治疗。登记提供真实世界高质量原始数据,虽面临后勤与流程挑战但优势大于弊端。
要点
- 登记型药物警戒可提供真实世界高质量原始数据,弥补自发报告和二手数据不足
- REGIMS为观察性多中心登记,评估多发性硬化免疫治疗副作用的发生率、类型和后果
- 多中心药物警戒登记建立面临后勤与流程挑战,但优势大于弊端
核心结论
- 登记型药物警戒如REGIMS提供特定患者群体真实世界照护环境下的高质量原始数据,支持无法用二手数据开展的药物警戒研究。
- 尽管在德国建立多中心药物警戒登记存在后勤与流程挑战,但其优势大于弊端。
研究设计与样本
- REGIMS为观察性、临床多中心登记,旨在评估多发性硬化免疫治疗副作用的发生率、类型和后果。
- 接受已批准多发性硬化药物治疗的患者由医生在医院、门诊和专科诊所常规访视时招募。
- REGIMS在各中心采用电子医生文档和纸质患者文档,均在基线和定期随访时记录。
- 截至2019年底,43个REGIMS中心活跃招募患者并进行随访文档记录。
主要发现
- 前1000例REGIMS患者中大多数为女性(69.3%)、复发缓解型多发性硬化(89.8%),并接受二线治疗。
- 在REGIMS实施过程中需克服若干后勤和流程挑战,本文对此进行了概述。
临床怎么用
- 登记型药物警戒可作为自发报告系统的补充,用于评估多发性硬化新免疫调节药物的长期和潜在罕见副作用。
- 多中心登记实施需设计电子医生文档与纸质患者文档并行的数据收集流程,并在基线和定期随访时记录。
局限性
- 自发药物不良反应病例报告系统存在若干局限性。
- 登记内原始数据收集面临若干挑战。
- 在德国建立多中心药物警戒登记存在后勤和流程挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The long-term and potential rare side effects of new immunomodulating drugs for the treatment of multiple sclerosis (MS) are often not well known. Spontaneous case report systems of adverse drug effects are a valuable source in pharmacovigilance, but have several limitations. Primary data collections within registries allow a comprehensive analysis of potential side effects, but face several challenges. This article will outline the chances and challenges of registry-based adverse event reporting, using the example of the German immunotherapeutic registry REGIMS. REGIMS is an observational, clinical multicenter registry that aims to assess the incidence, type, and consequences of side effects of MS immunotherapies. Patients treated with an approved MS medication are recruited by their physicians during routine visits in hospitals, outpatient clinics, and MS-specialized practices. REGIMS incorporates an electronic physician-based documentation in each center and a paper-based patient documentation, both at baseline and regular follow-up visits. By the end of 2019, 43 REGIMS centers were actively recruiting patients and performing follow-up documentations. The majority of the first 1000 REGIMS patients were female (69.3%), had relapse-remitting MS (89.8%), and were treated with a second-line therapy. During the implementation of REGIMS, several logistic and procedural challenges had to be overcome, which are outlined in this paper. Pharmacovigilance registries such as REGIMS provide high-quality primary data from a specific patient population in a real-world care setting and enable pharmacovigilance research that cannot be carried out using secondary data. Despite the logistic and procedural challenges in establishing a multicenter pharmacovigilance registry in Germany, the advantages outweigh the drawbacks.
引用
- Simbrich A, Thibaut J, Khil L, et al. Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry. Drug Saf. 2020. PMID: 33098059. doi:10.1007/s40264-020-01007-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。